Ankyra Therapeutics

Are you attending the Advancing Innovation in Dermatology, Inc. #InnovationForum today? If so, please be sure to see Ankyra Therapeutics CEO Howard Kaufman as a panelist discussing Innovation in the Non-Surgical Treatment of Cutaneous Malignancy by Local Delivery #anchoredimmunotherapy #DIF2025

Are you attending American Association for Cancer Research's Special Conference on ‘Translating Targeted Therapies in Combination with Radiotherapy’ in San Diego? Please make sure you attend Ankyra Therapeutics’s Sailaja Battula’s talk on 'Integrating Radiation Therapy in Combination with Anchored Immunotherapy for Solid Tumors' followed by panel discussion. Spotlight Session on ‘Industry perspectives on integrating radiation therapy with pharmaceutical treatments’ is on January 28th, 2025, at 1PM PT. #AACR #anchoredimmunotherapy

We're #hiring a new Senior/Principal Scientist, Translational Science in Cambridge, Massachusetts. Apply today or share this post with your network.

Ankyra Therapeutics announces an expanded collaboration with?Johnson & Johnson Innovative Medicine to advance the clinical development of ANK-101, an IL-12 anchored drug conjugate that is currently in Phase 1 clinical trials for solid tumors. #anchoredimmunotherapy #anchoreddrugconjugates https://lnkd.in/eCYcpVKG

Ankyra Therapeutics announces the first visceral tumor patient dosed #anchoredimmunotherapy #anchoreddrugconjugates https://shorturl.at/nclWG

Ankyra Therapeutics is excited to announce the appointment of Julia G. Butchko, Ph.D. and Tara Withington, CAE to the Ankyra Board of Directors. https://shorturl.at/UHkXq

Ankyra Therapeutics President and CEO Howard Kaufman will be speaking at today's SITC Summit on Intralesional Immunotherapy #SITC #Anchoredimmunotherapy #immunotherapy

Come see Ankyra Therapeutics Trial in Progress poster, A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors, at 9am CDT located at 158A #ASCO https://lnkd.in/ecSv2fxn

Come see Ankyra Therapeutics Trial in Progress poster, A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors, at 9am CDT located at 158A #ASCO https://lnkd.in/ecSv2fxn

Ankyra Therapeutics President and CEO will be the featured speaker at Drug Discovery News upcoming webinar about Combination therapy for Cancer on April 18, 2024 at 1pm ET https://lnkd.in/exKhS5NZ